[Prolonged response with paclitaxel after immunotherapy by pembrolizumab in lung cancer].

Abstract

INTRODUCTION Pembrolizumab, a humanized monoclonal antibody IgG4 anti-PD-1, having offered promising results in patients suffering from non-small cell lung cancer metastatic and heavily pretreated. OBSERVATION We report here the case of an unexpected good response after pembrolizumab failure obtained with paclitaxel in a 68-year-old patient with stage IV… (More)
DOI: 10.1016/j.pneumo.2016.05.004

Topics

4 Figures and Tables